Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

Urpo Kiiskinen1 Eli Lilly, Helsinki, Finland;, Germany

Stephan Matthaei2 Quakenbrück Diabetes Center, Quakenbrück, Germany

Matthew Reaney3 Eli Lilly, Windlesham, Surrey, UK

Chantal Mathieu4 Department of Endocrinology, UZ Gasthuisberg, Leuven, Belgium

Claes-Göran Östenson5 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Thure Krarup6 Department of Endocrinology, Bispebjerg Hospital, Copenhagen, Denmark

Michael Theodorakis7 Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Jacek Kiljański8 Eli Lilly, Warsaw, Poland

Carole Salaun-Martin9 Eli Lilly, Neuilly Cedex, France

Hélène Sapin9 Eli Lilly, Neuilly Cedex, France

Bruno Guerci10 Department of Diabetes, Metabolic Diseases, and Nutrition, Hôpital Brabois, Vandoeuvre-Lès-Nancy, FranceCorrespondence[email protected]

show all

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date